Literature DB >> 12515730

Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.

Leticia Quintanilla-Martinez1, Theresa Davies-Hill, Falko Fend, Julia Calzada-Wack, Lynn Sorbara, Elias Campo, Elaine S Jaffe, Mark Raffeld.   

Abstract

p27 is a cyclin-dependent kinase inhibitor that plays a critical role in regulating G(1)/S progression, and whose activity is, in part, regulated through interactions with D-type cyclins. Mantle cell lymphoma (MCL) is characterized by the t(11;14) translocation resulting in deregulated cyclin D1. We previously showed that p27 expression in MCL, as assessed by immunohistochemistry (IHC), does not show the usual inverse relationship to proliferate seen in most other lymphomas that do not overexpress cyclin D1. This suggested that the normal expression or control of p27 activity on cell growth might be altered through potential interactions with cyclin D1. Using Western blot and coimmunoprecipitation studies, we assessed the interrelationship between cyclin D1 and p27 in several cyclin D1(+) cell lines and primary MCL cases. Similar to our previous results by IHC, typical MCLs showed lower expression of p27 when compared to the more highly proliferative blastic cases or cell lines (mean arbitrary units: 58 versus 236 versus 120). Cyclin D1 was expressed at variable levels in both typical and blastic MCLs. p27 protein could be consistently coimmunoprecipitated with cyclin D1 from both cell lines and cases. Using techniques of exhaustive immunoprecipitation, we could demonstrate that most p27 protein was sequestered into complexes containing cyclin D1. We hypothesize that mantle cell lymphomagenesis results not only from direct consequences of inappropriate cyclin D1 expression, but also from the ability of overexpressed cyclin D1 to buffer physiologic changes in p27 levels, thereby rendering p27 ineffective as an inhibitor of cellular growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12515730     DOI: 10.1182/blood-2002-01-0263

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

2.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

3.  Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

Authors:  Tiffany Tang; Peter Martin
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

4.  Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.

Authors:  Yoko Tabe; Linhua Jin; Marina Konopleva; Masato Shikami; Shinya Kimura; Michael Andreeff; Mark Raffeld; Takashi Miida
Journal:  Acta Haematol       Date:  2013-09-19       Impact factor: 2.195

Review 5.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

6.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

7.  Patterns of p57Kip2 expression in embryonic rat brain suggest roles in progenitor cell cycle exit and neuronal differentiation.

Authors:  Weizhen Ye; Georges Mairet-Coello; Elise Pasoreck; Emanuel Dicicco-Bloom
Journal:  Dev Neurobiol       Date:  2009-01       Impact factor: 3.964

8.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

Authors:  Leticia Quintanilla-Martinez; Julia Slotta-Huspenina; Ina Koch; Margit Klier; Eric D Hsi; Laurence de Leval; Wolfram Klapper; Stefan Gesk; Reiner Siebert; Falko Fend
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

Authors:  Yoko Tabe; Denise Sebasigari; Linhua Jin; Martina Rudelius; Theresa Davies-Hill; Kazunori Miyake; Takashi Miida; Stefania Pittaluga; Mark Raffeld
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

10.  Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells.

Authors:  Verónica Parrillas; Laura Martínez-Muñoz; Borja L Holgado; Amit Kumar; Graciela Cascio; Pilar Lucas; José Miguel Rodríguez-Frade; Marcos Malumbres; Ana C Carrera; Karel Hm van Wely; Mario Mellado
Journal:  Cell Mol Life Sci       Date:  2012-09-23       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.